Skip to main content
NCBI home page
Frontiers in Aging Neuroscience logoLink to Frontiers in Aging Neuroscience
. 2017 May 26;9:148. doi: 10.3389/fnagi.2017.00148

Role of Atypical Chemokine Receptors in Microglial Activation and Polarization

Valentina Salvi 1,†, Francesca Sozio 1,2,†, Silvano Sozzani 1,2,*,‡, Annalisa Del Prete 1,2,‡
PMCID: PMC5445112  PMID: 28603493

Abstract

Inflammatory reactions occurring in the central nervous system (CNS), known as neuroinflammation, are key components of the pathogenic mechanisms underlying several neurological diseases. The chemokine system plays a crucial role in the recruitment and activation of immune and non-immune cells in the brain, as well as in the regulation of microglia phenotype and function. Chemokines belong to a heterogeneous family of chemotactic agonists that signal through the interaction with G protein-coupled receptors (GPCRs). Recently, a small subset of chemokine receptors, now identified as “atypical chemokine receptors” (ACKRs), has been described. These receptors lack classic GPCR signaling and chemotactic activity and are believed to limit inflammation through their ability to scavenge chemokines at the inflammatory sites. Recent studies have highlighted a role for ACKRs in neuroinflammation. However, in the CNS, the role of ACKRs seems to be more complex than the simple control of inflammation. For instance, CXCR7/ACKR3 was shown to control T cell trafficking through the regulation of CXCL12 internalization at CNS endothelial barriers. Furthermore, D6/ACKR2 KO mice were protected in a model of experimental autoimmune encephalomyelitis (EAE). D6/ACKR2 KO showed an abnormal accumulation of dendritic cells at the immunization and a subsequent impairment in T cell priming. Finally, CCRL2, an ACKR-related protein, was shown to play a role in the control of the resolution phase of EAE. Indeed, CCRL2 KO mice showed exacerbated, non-resolving disease with protracted inflammation and increased demyelination. This phenotype was associated with increased microglia and macrophage activation markers and imbalanced M1 vs. M2 polarization. This review will summarize the current knowledge on the role of the ACKRs in neuroinflammation with a particular attention to their role in microglial polarization and function.

Keywords: chemokine receptors, neuroinflammation, microglia, atypical chemokine receptors, CCRL2

Introduction

The central nervous system (CNS) degeneration, which characterizes several chronic neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), is closely linked to immune activation occurring in the CNS called neuroinflammation (Ransohoff, 2016a). Regardless the triggering mechanisms that can include viral infections, immune-mediate disorders and neuron damage, the immune activation involves microglia and astrocytes (Sofroniew and Vinters, 2010; Perry and Teeling, 2013). These cells represent immune cells resident in the CNS, which regulate CNS homeostasis from the development of brain to the adult life and aging (Schwartz et al., 2013). In particular, any insult is followed by activation of microglia, which culminates with the production of a series of pro-inflammatory mediators that alter brain-blood barrier permeability and induce infiltration of circulating leukocytes inside the CNS (Noh et al., 2014). This effect is regulated by the chemokine system which plays an important role in the control of immune surveillance in the brain (Takeshita and Ransohoff, 2012). The inflammatory response is usually self-limiting and culminates with tissue repair and resolution mechanisms, which mostly involve M2 polarized microglia. However, when this process persists and become chronic, the long-standing activation state of microglia sustains the release of detrimental inflammatory mediators and neurotoxic products which contribute to neurodegenerative sequelae (González et al., 2014; Ransohoff, 2016a).

This review article will focus on the mechanisms involved in the tight regulation of local immune responses occurring during CNS inflammatory process, with particular attention to the role of the chemokine system and atypical chemokine receptors (ACKRs) in microglial activation and polarization.

Microglial Activation and Polarization

Microglia are tissue-resident macrophages of the brain and spinal cord, derived from primitive myeloid progenitors in the yolk sac that invade the brain parenchyma during embryonic development (Ginhoux et al., 2010). As mononuclear phagocytes of the CNS, microglia play an important role in maintaining normal brain functions in both physiological and pathological conditions (Wolf et al., 2017). In CNS development, microglia regulate neurogenesis by phagocyting apoptotic newborn cells in the sub-granular zone (Sierra et al., 2010) and support neuronal survival by accumulating around axons and secreting trophic factors like IGF-1 (Ueno et al., 2013). In addition, microglia actively remove the excess of synaptic connections and play a major role in synaptic pruning during postnatal development in mice (Paolicelli et al., 2011). In physiological conditions microglia are responsible to eliminate and remodel synapses and support myelin turnover by phagocytosis of axon terminals and dendritic spines also in adult brain (Tremblay, 2011). Morphology of microglia reveals the different activation states of these cells. In healthy brain, microglia have a ramified shape with extensively branched processes in contact with neurons, astrocytes and blood vessels, that continually survey and monitor changes in the local milieu (Nimmerjahn et al., 2005). Once activated by tissue damage, viral or bacterial insults or pro-inflammatory stimuli these cells develop ameboid morphology characterized by cell body enlargement, shortened cell processes and the presence of numerous cytoplasmic vacuoles, associated with phagocytosis and pro-inflammatory functions (Djukic et al., 2006; Colonna and Butovsky, 2017). Microglia like macrophages are plastic cells able to acquire distinct functional phenotypes according to the nature of the local microenvironment (Figure 1). In addition to morphological differentiation, these cells express different surface markers such as Toll-like receptors, NOD-like receptors, nucleotide-binding oligomerization domain and scavenger receptors. In response to pro-inflammatory stimuli, like LPS, IFNγ and TNF-α, microglial cells produce inflammatory cytokines such as IL-1α/β, IL-6, IL-12, IL-23, TNF-α, iNOS, CCL5 and express Fc receptors CD16, CD32, CD64 and CD68. This pro-inflammatory polarization corresponds to the “classical” M1 activation state (Boche et al., 2013; Cherry et al., 2014). On the other hand, anti-inflammatory stimuli such as IL-4, IL-10, IL-13, TGF-β and glucocorticoids polarize microglia in the “alternative” M2 phenotype that promotes resolution of inflammation and restoring of homeostasis. M2 polarized cells produce anti-inflammatory molecules like arginase-1 (Arg-1), that contributes to matrix deposition and wound healing, growth factors like IGF-1, chitinase 3-like 3 (Ym-1) and FIZZ1 which promote deposition of extracellular matrix and express characteristic receptors of M2 phagocytes such as mannose receptor (CD206) and TREM2 (Raes et al., 2002; Orihuela et al., 2016). Activation of microglial cells strongly influence the pathogenesis of neuroinflammatory and neurodegenerative diseases such as PD, ALS, MS, AD, traumatic brain injuries, stroke and brain tumors (Wolf et al., 2017). However, the concept of microglia polarization is now debated, since M1/M2 paradigm may represent an oversimplification of in vivo activation. Transcriptomic and proteomic analysis will help to define the heterogeneity of microglial phenotype associated to different pathological contexts (Ransohoff, 2016b).

Figure 1.

Figure 1

Open in a new tab

Activation and polarization of microglia in resting conditions and during neuroinflammation. The morphology and the phenotype associated with different functional states of microglia are represented. In physiological conditions patrolling microglia regulate central nervous system (CNS) homeostasis. In neuroinflammation microglia assume ameboid morphology and acquire classical M1 or alternative M2 phenotype according to the nature of local milieu.

Chemokine System in Neuroinflammation

Chemokines are small, secreted chemotactic cytokines involved in leukocyte trafficking both in homeostatic and inflammatory conditions. Chemokines play their functional role by the engagement of the cognate G protein-coupled receptors (GPCRs), which results in the receptor activation and the triggering of intracellular signaling cascade that regulates several cell activities such as migration, adhesion, phagocytosis, cytokine secretion, proliferation and apoptosis (Bachelerie et al., 2014a). More than 50 different chemokines and about 20 chemokine receptors have been discovered (Bachelerie et al., 2014a). Chemokines are divided into CC, CXC, XC and CX3C subfamilies according to the specific nature of the cysteine motif (Zlotnik and Yoshie, 2000). The chemokine system displays promiscuity features in ligand binding and chemokine receptor expression on different leukocytes (Bachelerie et al., 2014a).

In CNS, chemokines play a role in physiological conditions being involved in neuronal migration, cell proliferation and synaptic activities. During neuroinflammation, in addition to their primary role in leukocytes recruitment, they can also have direct effects on neuronal cells and mediate the cross talk between neurons and inflammatory cells (Cartier et al., 2005). Chemokines can exert neuroprotective role. For instance, CCL2 was described to play a role as a protective agent against the toxic effects of glutamate and HIV-tat-induced apoptosis (Eugenin et al., 2003). In addition, the signaling of the neuronal CX3CL1 and its receptor CX3CR1 were shown to reduce the levels of neurotoxic substances such as TNF-α and nitric oxide in activated microglia during neuroinflammation (Mattison et al., 2013). On the contrary, chemokines can directly induce neuronal death or indirectly through the activation of microglia killing mechanisms (Sui et al., 2006; Yang et al., 2011). A new role for chemokines in the modulation of the release of neuropeptides and neurotransmitters was also proposed (Rostène et al., 2007, 2011), as shown by the effect of CXCL12 in tuning the firing pattern of vasopressin neurons (Callewaere et al., 2006).

In active MS patients, the pathogenic Th1 axis, involving CXCL10, CCL3, CCL4, CCL5 and the receptors CXCR3 and CCR5, is activated in blood and cerebrospinal fluid (Uzawa et al., 2010). On the contrary, the Th2 receptors CCR4 and CCR3 and the ligand CCL2 play a protective role (Nakajima et al., 2004). Th17 are recruited by CCR6/CCL20 axis expressed by epithelial cells of choroid plexus as shown in the experimental autoimmune encephalomyelitis (EAE) model (Reboldi et al., 2009; Cao et al., 2015). CXCL12 acts as double edge sword since it is responsible for the recruitment of monocytes in the CNS during MS (Azin et al., 2012) and, at the same time, contributes to remyelination and neuroprotection processes (Khorramdelazad et al., 2016). Moreover, in MS, CXCL13 secreted by microglia has been shown to be involved in the recruitment of CXCR5 expressing Th1, Th17 and B cells (Huber and Irani, 2015).

The dysregulation of the CX3CL1-CX3CR1 communications between neurons and microglia has been investigated in AD patients showing opposite effects. In one study CX3CR1 deficiency was reported to reduce beta-amyloid deposition in AD experimental model (Lee et al., 2010). Other work showed different contribution of the soluble vs. the membrane-bound forms of CX3CL1 in the regulation of microglial phagocytosis of plaques (Cho et al., 2011; Lee et al., 2014). CX3CL1 gene expression was upregulated in the brain of AD patient (Strobel et al., 2015). Other chemokines, such as CCL3, CXCL10 and CCL2 were implicated in the regulation of glial activity involved in neuroinflammation and neurotoxic environment during the AD development (Xia et al., 2000; Galimberti et al., 2006; Meyer-Luehmann et al., 2008; Dos Passos et al., 2016). A relevant role of glial activation in the development of neuroinflammation associated with damage of the nigro-striatal dopaminergic system was suggested in PD (Przedborski, 2010). The CXCL12 and CXCR4 expression is increased and can promote apoptosis of dopamine neurons (Shimoji et al., 2009). On the contrary, CX3CL1 exerts a neuroprotective effect during PD development (Pabon et al., 2011).

Overall, neuroinflammation is a complex process involved in several CNS diseases ranging from autoimmune to degenerative pathologies and chemokine system plays key role in immune surveillance, in microglial activation and functions, in neurocommunications among several CNS cell types and can orchestrate both neuroprotective and detrimental effects.

Atypical Chemokine Receptors in Neuroinflammation

ACKRs represent a small subset of proteins expressing high degree of homology with chemokine receptors. Since ACKRs lack structural domains required for proper Gαi signaling, they are unable to activate canonical G protein-dependent receptor signaling and chemotactic functions (Bachelerie et al., 2014a,b). At the moment, the ACKR family includes four proteins, namely ACKR1, ACKR2, ACKR3 and ACKR4. Other two proteins, namely CCRL2 and PITPNM3 have been provisionally included with the name of “Ackr5” and “Ackr6”, respectively, but they still need formal approval (Bachelerie et al., 2014b). In the last few years, the role of ACKRs is gradually clarifying since they were shown to regulate inflammation acting as scavenger receptors, promoting chemokine transcytosis or regulating chemokine gradient formation (Mantovani et al., 2001; Nibbs and Graham, 2013; Bachelerie et al., 2014a,b; Bonecchi and Graham, 2016). The role of ACKRs in neuroinflammation is described below and summarized in Table 1.

Table 1.

Atypical chemokine receptors (ACKRs) and their role in neuroinflammation.

Receptor name Alternative names Sites of expression Role in neuroinflammation References
ACKR1 Duffy antigen receptor for chemokines (DARC), CD234 Erythrocytes Vascular endothelial cells Purkinje cells On erythrocyte it acts as chemokine reservoir On endothelium it contributes to EAE pathogenesis Minten et al. (2014)
ACKR2 CCBP2, D6, CMKBR9 Lymphatic endothelial cells Innate-like B cells Keratinocytes Trophoblasts It is required for generating T cell responses in EAE It suppresses Th17 responses in EAE Liu et al. (2006), Hansell et al. (2015)
ACKR3 RDC1, CXCR7, CMKOR1 Endothelial cells Hematopoietic cells, Mesenchymal cells Neurons Astrocytes It contributes to EAE pathogenesis It mediates chemotaxis of activated microglia during EAE Cruz-Orengo et al. (2011b); Bao et al. (2016)
ACKR4 CCRL1, CCXCKR, CCR11 Thymic epithelial cells Keratinocytes Lymphatic endothelial cells It delays the onset of EAE and reduces disease severity Comerford et al. (2010)
Open in a new tab

ACKR1

ACKR1 binds, with high affinity over 20 inflammatory chemokines belonging to the CC and CXC families (Novitzky-Basso and Rot, 2012). ACKR1 is expressed on erythrocytes, cerebellar Purkinje cells, postcapillary venules and capillary endothelial cells. Depending on its cellular expression, the biological functions of ACKR1 are quite different. Indeed, ACKR1 expressed by erythrocytes regulates the bioavailability of circulating chemokines by binding them with high affinity (Schnabel et al., 2010), while endothelial ACKR1 induces chemokine internalization and transcytosis from the basolateral to the luminal side of endothelium, where the chemokines are immobilized and contribute to leukocyte extravasation in vivo (Pruenster et al., 2009). In neuroinflammation, ACKR1 is upregulated on endothelial cells in CNS microvessels during EAE and in MS where it mediates the abluminal to luminal transport of inflammatory chemokines across the blood-brain barrier and contributes to EAE pathogenesis (Minten et al., 2014). In bone marrow chimera experiments, ACKR1 expression in erythrocytes was shown to be responsible for the increased plasma levels of inflammatory chemokines observed during EAE. However, for the full development of the disease, the expression of ACKR1 was necessary also on endothelial cells (Minten et al., 2014).

ACKR2

ACKR2 binds a broad panel of inflammatory CC chemokines and is expressed by lymphatic endothelial cells, trophoblasts, keratinocytes and some leukocyte subsets, mostly innate-like B cells (Lee et al., 2013). ACKR2 binds and internalizes its ligands and target them for lysosomal degradation. Therefore, ACKR2 is a chemokine-scavenging receptor, aiding the resolution of inflammatory reactions (Graham, 2009). Studies in EAE model suggested that ACKR2 functions may be context-dependent. Indeed, ACKR2 KO mice are unexpectedly resistant to the induction of EAE due to impaired encephalitogenic responses (Liu et al., 2006). This observation is ascribed to defective T-cell priming resulting by the suppression of dendritic cells migration to the lymph nodes caused by excessive inflammation at the immunization site (Liu et al., 2006). In contrast, ACKR2 deficiency was recently associated with an exacerbated EAE phenotype when mice were immunized with the entire protein but not the MOG peptide, suggesting a regulatory role for ACKR2 mediated by T cell polarization (Hansell et al., 2015).

ACKR3

ACKR3 binds two chemokines, namely CXCL12 and CXCL11. ACKR3 is expressed by endothelial cells, some hematopoietic cells, mesenchymal cells, neurons and astrocytes. ACKR3 is able to internalize CXCL12 and modulate CXCR4 expression and signaling by forming heterodimers with CXCR4 (Levoye et al., 2009; Décaillot et al., 2011). Thus, ACKR3 can control chemokine responsiveness by regulating CXCR4 protein levels and CXCL12 scavenging activity as shown in migrating cortical interneurons (Sánchez-Alcañiz et al., 2011; Abe et al., 2014). Loss of CXCL12, a chemokine that restricts the CNS entry of CXCR4-expressing leukocytes from abluminal surfaces of blood-brain barriers, has been described in MS. During EAE, ACKR3 expression on endothelial barriers is increased at sites of inflammatory infiltration (Cruz-Orengo et al., 2011b) and its activation, by scavenging CXCL12, is essential for leukocyte entry via endothelial barriers into the CNS parenchyma (Cruz-Orengo et al., 2011b). Administration of ACKR3 specific antagonist CCX771 increases abluminal levels of CXCL12 at the blood-brain barrier, preventing the pathological entry of immune cells into CNS parenchyma, thus improving clinical signs of EAE disease (Cruz-Orengo et al., 2011b). In addition, ACKR3 antagonism during EAE helps preserving axonal integrity (Cruz-Orengo et al., 2011a). In mice with EAE, ACKR3 is also upregulated in migrating oligodendrocytes progenitors, important cells for the remyelination process, in the subventricular zone (Banisadr et al., 2016). More recently, it was reported that ACKR3 expression is responsible for the migration of activated microglia and positively correlated with the clinical severity of EAE (Bao et al., 2016). Indeed, an ACKR3 neutralizing antibody modulates microglial chemotaxis and ameliorates EAE symptoms (Bao et al., 2016).

ACKR4

ACKR4 binds the homeostatic CC chemokines CCL19, CCL21, CCL25 and with lower affinity CXCL13. ACKR4 is expressed by thymic epithelial cells, keratinocytes and lymphatic endothelial cells. After chemokine binding ACKR4 internalizes and drives its ligand to degradation (Comerford et al., 2006), thus representing the homeostatic counterpart of the inflammatory CC chemokine scavenger receptor ACKR2. In an EAE model, ACKR4 deficient mice developed the disease earlier and with more severity compared to wild type mice. This earlier onset was associated with an enhanced splenic Th17-type response, an elevated expression of IL-23 transcript, and an increase in CCL21 in the CNS (Comerford et al., 2010).

Role of CCRL2 in Microglial Polarization

CCRL2 is a seven transmembrane protein that shares some structural and functional aspects with ACKRs, such as the lack of conventional GPCR signaling and the inability to induce cell migration (Zabel et al., 2008; Del Prete et al., 2013; Bachelerie et al., 2014a; De Henau et al., 2016). Some authors described binding and/or functional activation of CCRL2 in response to chemokines CCL2, CCL5, CCL7, CCL8 and CCL19 (Biber et al., 2003; Catusse et al., 2010; Leick et al., 2010). However, these results were not subsequently confirmed by other groups (Del Prete et al., 2013; De Henau et al., 2016). CCRL2 binds and presents chemerin, a non-chemokine chemotactic protein, to adjacent cells expressing the functional chemerin receptor ChemR23, and acts as regulator of chemerin bioavailability (Zabel et al., 2008; Gonzalvo-Feo et al., 2014). Neither internalization nor calcium mobilization was described upon chemerin binding (Zabel et al., 2008). CCRL2 is expressed by endothelial and epithelial cells, and by a variety of leukocytes, including macrophages, dendritic cells, mast cells and neutrophils and its expression is increased by pro-inflammatory stimuli (Galligan et al., 2004; Zabel et al., 2008; Otero et al., 2010; Monnier et al., 2012; Del Prete et al., 2013; Gonzalvo-Feo et al., 2014). In particular, CCRL2 was described to play a non-redundant role in the regulation of dendritic cell migration during airway inflammation (Otero et al., 2010). Moreover, in vitro and in vivo studies showed CCRL2 expression in mouse microglia and astrocytes and upregulation in macrophages in the EAE model (Zuurman et al., 2003; Brouwer et al., 2004). To better understand the role of CCRL2 in CNS physiopathology, our group studied the role of CCRL2 deficiency in EAE model (Mazzon et al., 2016).

CCRL2 expression was found upregulated following MOGaa35–55 immunization and paralleled the kinetics of the clinical symptoms, reaching the peak induction at the acme of the disease and declining thereafter (Mazzon et al., 2016). During the development of EAE, the upregulation of CCRL2 was associated with increased levels of chemerin (Graham et al., 2009; Mazzon et al., 2016), mimicking the regulation of ACKR3 and its ligand CXCL12 (Banisadr et al., 2016). CCRL2 deficient mice showed exacerbated EAE clinical phenotype, in terms of increased mortality, higher maximum and cumulative clinical score. The histopathological analysis revealed an intense and persistent inflammatory reaction associated with increased demyelination in CCRL2 deficient spinal cords at the recovery phase of the disease. These observations were paralleled by the increase in T cell infiltration in CCRL2 deficient mice. In addition, in CCRL2 KO mice, the macrophage/microglia activation markers, namely Iba-1, CD68, and TREM2 remained elevated during the recovery phase of the disease. An unbalanced M1/M2 polarization, with a persistent predominance of the M1 markers was also observed during the recovery phase of the disease. This was in contrast to control mice that developed all the signs of resolution of inflammation including the M2 phenotype characterizing the CNS regenerative response. These results candidate CCRL2 as an important player in EAE-associated inflammatory reactions and suggest the tuning of microglial activation and polarization as an additional mechanism used by ACKRs to regulate CNS inflammatory responses.

Conclusions

Neuroinflammation is a key component of neurodegenerative diseases. This process involves the effector components of both innate and adaptive immunity. In the CNS, microglia represent the resident immune component involved in tissue homeostasis. Being an immune sensor of altered homeostasis, microglia accumulate in response to neuron injury and after the entry of foreign substances in the CNS. The way microglia become activated represents a crucial element in the regulation of neuroinflammation and may be associated with either beneficial or detrimental effects resulting in neuroprotection or neurotoxicity. The chemokine system plays multiple roles in the modulation of this multifaceted process. Our growing understanding on the functions of the ACKRs increases the level of complexity of this scenario and provides new potential targets to be exploited in the control of neuroinflammation.

Author Contributions

VS and FS wrote and edited the manuscript and prepared the Table and Figure. SS and ADP contributed in writing and supervised the final version of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC); Interuniversity Attraction Poles (IAP) 7-40 program.

References

  1. Abe P., Mueller W., Schütz D., MacKay F., Thelen M., Zhang P., et al. (2014). CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons. Development 141, 1857–1863. 10.1242/dev.104224 [DOI] [PubMed] [Google Scholar]
  2. Azin H., Vazirinejad R., Ahmadabadi B. N., Khorramdelazad H., Zarandi E. R., Arababadi M. K., et al. (2012). The SDF-1 3′a genetic variation of the chemokine SDF-1α (CXCL12) in parallel with its increased circulating levels is associated with susceptibility to MS: a study on Iranian multiple sclerosis patients. J. Mol. Neurosci. 47, 431–436. 10.1007/s12031-011-9672-6 [DOI] [PubMed] [Google Scholar]
  3. Bachelerie F., Ben-Baruch A., Burkhardt A. M., Combadiere C., Farber J. M., Graham G. J., et al. (2014a). International union of basic and clinical pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66, 1–79. 10.1124/pr.113.007724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bachelerie F., Graham G. J., Locati M., Mantovani A., Murphy P. M., Nibbs R., et al. (2014b). New nomenclature for atypical chemokine receptors. Nat. Immunol. 15, 207–208. 10.1038/ni.2812 [DOI] [PubMed] [Google Scholar]
  5. Banisadr G., Podojil J. R., Miller S. D., Miller R. J. (2016). Pattern of CXCR7 gene expression in mouse brain under normal and inflammatory conditions. J. Neuroimmune Pharmacol. 11, 26–35. 10.1007/s11481-015-9616-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bao J., Zhu J., Luo S., Cheng Y., Zhou S. (2016). CXCR7 suppression modulates microglial chemotaxis to ameliorate experimentally-induced autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 469, 1–7. 10.1016/j.bbrc.2015.11.059 [DOI] [PubMed] [Google Scholar]
  7. Biber K., Zuurman M. W., Homan H., Boddeke H. W. (2003). Expression of L-CCR in HEK 293 cells reveals functional responses to CCL2, CCL5, CCL7, and CCL8. J. Leukoc. Biol. 74, 243–251. 10.1189/jlb.0802415 [DOI] [PubMed] [Google Scholar]
  8. Boche D., Perry V. H., Nicoll J. A. (2013). Review: activation patterns of microglia and their identification in the human brain. Neuropathol. Appl. Neurobiol. 39, 3–18. 10.1111/nan.12011 [DOI] [PubMed] [Google Scholar]
  9. Bonecchi R., Graham G. J. (2016). Atypical chemokine receptors and their roles in the resolution of the inflammatory response. Front. Immunol. 7:224. 10.3389/fimmu.2016.00224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Brouwer N., Zuurman M. W., Wei T., Ransohoff R. M., Boddeke H. W., Biber K. (2004). Induction of glial L-CCR mRNA expression in spinal cord and brain in experimental autoimmune encephalomyelitis. Glia 46, 84–94. 10.1002/glia.10352 [DOI] [PubMed] [Google Scholar]
  11. Callewaere C., Banisadr G., Desarménien M. G., Mechighel P., Kitabgi P., Rostène W. H., et al. (2006). The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4. Proc. Natl. Acad. Sci. U S A 103, 8221–8226. 10.1073/pnas.0602620103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cao Y., Goods B. A., Raddassi K., Nepom G. T., Kwok W. W., Love J. C., et al. (2015). Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci. Transl. Med. 7:287ra274. 10.1126/scitranslmed.aaa8038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cartier L., Hartley O., Dubois-Dauphin M., Krause K. H. (2005). Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res. Rev. 48, 16–42. 10.1016/j.brainresrev.2004.07.021 [DOI] [PubMed] [Google Scholar]
  14. Catusse J., Leick M., Groch M., Clark D. J., Buchner M. V., Zirlik K., et al. (2010). Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia. Mol. Cancer 9:297. 10.1186/1476-4598-9-297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cherry J. D., Olschowka J. A., O’Banion M. K. (2014). Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation 11:98. 10.1186/1742-2094-11-98 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cho S. H., Sun B., Zhou Y., Kauppinen T. M., Halabisky B., Wes P., et al. (2011). CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 286, 32713–32722. 10.1074/jbc.M111.254268 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Colonna M., Butovsky O. (2017). Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 35, 441–468. 10.1146/annurev-immunol-051116-052358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Comerford I., Milasta S., Morrow V., Milligan G., Nibbs R. (2006). The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur. J. Immunol. 36, 1904–1916. 10.1002/eji.200535716 [DOI] [PubMed] [Google Scholar]
  19. Comerford I., Nibbs R. J., Litchfield W., Bunting M., Harata-Lee Y., Haylock-Jacobs S., et al. (2010). The atypical chemokine receptor CCX-CKR scavenges homeostatic chemokines in circulation and tissues and suppresses Th17 responses. Blood 116, 4130–4140. 10.1182/blood-2010-01-264390 [DOI] [PubMed] [Google Scholar]
  20. Cruz-Orengo L., Chen Y. J., Kim J. H., Dorsey D., Song S. K., Klein R. S. (2011a). CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivo axial diffusivity. J. Neuroinflammation 8:170. 10.1186/1742-2094-8-170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Cruz-Orengo L., Holman D. W., Dorsey D., Zhou L., Zhang P., Wright M., et al. (2011b). CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J. Exp. Med. 208, 327–339. 10.1084/jem.20102010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. De Henau O., Degroot G. N., Imbault V., Robert V., De Poorter C., McHeik S., et al. (2016). Signaling properties of chemerin receptors CMKLR1, GPR1 and CCRL2. PLoS One 11:e0164179. 10.1371/journal.pone.0164179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Décaillot F. M., Kazmi M. A., Lin Y., Ray-Saha S., Sakmar T. P., Sachdev P. (2011). CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J. Biol. Chem. 286, 32188–32197. 10.1074/jbc.M111.277038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Del Prete A., Bonecchi R., Vecchi A., Mantovani A., Sozzani S. (2013). CCRL2, a fringe member of the atypical chemoattractant receptor family. Eur. J. Immunol. 43, 1418–1422. 10.1002/eji.201243179 [DOI] [PubMed] [Google Scholar]
  25. Djukic M., Mildner A., Schmidt H., Czesnik D., Brück W., Priller J., et al. (2006). Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain 129, 2394–2403. 10.1093/brain/awl206 [DOI] [PubMed] [Google Scholar]
  26. Dos Passos G. R., Sato D. K., Becker J., Fujihara K. (2016). Th17 cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications. Mediators Inflamm. 2016:5314541. 10.1155/2016/5314541 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Eugenin E. A., D’Aversa T. G., Lopez L., Calderon T. M., Berman J. W. (2003). MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J. Neurochem. 85, 1299–1311. 10.1046/j.1471-4159.2003.01775.x [DOI] [PubMed] [Google Scholar]
  28. Galimberti D., Fenoglio C., Lovati C., Venturelli E., Guidi I., Corrà B., et al. (2006). Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease. Neurobiol. Aging 27, 1763–1768. 10.1016/j.neurobiolaging.2005.10.007 [DOI] [PubMed] [Google Scholar]
  29. Galligan C. L., Matsuyama W., Matsukawa A., Mizuta H., Hodge D. R., Howard O. M., et al. (2004). Up-regulated expression and activation of the orphan chemokine receptor, CCRL2, in rheumatoid arthritis. Arthritis Rheum. 50, 1806–1814. 10.1002/art.20275 [DOI] [PubMed] [Google Scholar]
  30. Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., et al. (2010). Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845. 10.1126/science.1194637 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. González H., Elgueta D., Montoya A., Pacheco R. (2014). Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J. Neuroimmunol. 274, 1–13. 10.1016/j.jneuroim.2014.07.012 [DOI] [PubMed] [Google Scholar]
  32. Gonzalvo-Feo S., Del Prete A., Pruenster M., Salvi V., Wang L., Sironi M., et al. (2014). Endothelial cell-derived chemerin promotes dendritic cell transmigration. J. Immunol. 192, 2366–2373. 10.4049/jimmunol.1302028 [DOI] [PubMed] [Google Scholar]
  33. Graham G. J. (2009). D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur. J. Immunol. 39, 342–351. 10.1002/eji.200838858 [DOI] [PubMed] [Google Scholar]
  34. Graham K. L., Zabel B. A., Loghavi S., Zuniga L. A., Ho P. P., Sobel R. A., et al. (2009). Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease. J. Immunol. 183, 6717–6723. 10.4049/jimmunol.080343 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hansell C. A., MacLellan L. M., Oldham R. S., Doonan J., Chapple K. J., Anderson E. J., et al. (2015). The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens. Immunol. Cell Biol. 93, 167–176. 10.1038/icb.2014.90 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Huber A. K., Irani D. N. (2015). Targeting CXCL13 during neuroinflammation. Adv. Neuroimmune. Biol. 6, 1–8. 10.3233/nib-150101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Khorramdelazad H., Bagheri V., Hassanshahi G., Zeinali M., Vakilian A. (2016). New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis. J. Neuroimmunol. 290, 70–75. 10.1016/j.jneuroim.2015.11.021 [DOI] [PubMed] [Google Scholar]
  38. Lee K. M., Nibbs R. J., Graham G. J. (2013). D6: the ‘crowd controller’ at the immune gateway. Trends Immunol. 34, 7–12. 10.1016/j.it.2012.08.001 [DOI] [PubMed] [Google Scholar]
  39. Lee S., Varvel N. H., Konerth M. E., Xu G., Cardona A. E., Ransohoff R. M., et al. (2010). CX3CR1 deficiency alters microglial activation and reduces β-amyloid deposition in two Alzheimer’s disease mouse models. Am. J. Pathol. 177, 2549–2562. 10.2353/ajpath.2010.100265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Lee S., Xu G., Jay T. R., Bhatta S., Kim K. W., Jung S., et al. (2014). Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J. Neurosci. 34, 12538–12546. 10.1523/JNEUROSCI.0853-14.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Leick M., Catusse J., Follo M., Nibbs R. J., Hartmann T. N., Veelken H., et al. (2010). CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology 129, 536–546. 10.1111/j.1365-2567.2009.03209.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. (2009). CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113, 6085–6093. 10.1182/blood-2008-12-196618 [DOI] [PubMed] [Google Scholar]
  43. Liu L., Graham G. J., Damodaran A., Hu T., Lira S. A., Sasse M., et al. (2006). Cutting edge: the silent chemokine receptor D6 is required for generating T cell responses that mediate experimental autoimmune encephalomyelitis. J. Immunol. 177, 17–21. 10.4049/jimmunol.177.1.17 [DOI] [PubMed] [Google Scholar]
  44. Mantovani A., Locati M., Vecchi A., Sozzani S., Allavena P. (2001). Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 22, 328–336. 10.1016/s1471-4906(01)01941-x [DOI] [PubMed] [Google Scholar]
  45. Mattison H. A., Nie H., Gao H., Zhou H., Hong J. S., Zhang J. (2013). Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice. J. Neuroimmunol. 257, 110–115. 10.1016/j.jneuroim.2013.02.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Mazzon C., Zanotti L., Wang L., Del Prete A., Fontana E., Salvi V., et al. (2016). CCRL2 regulates M1/M2 polarization during EAE recovery phase. J. Leukoc. Biol. 99, 1027–1033. 10.1189/jlb.3ma0915-444RR [DOI] [PubMed] [Google Scholar]
  47. Meyer-Luehmann M., Spires-Jones T. L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., et al. (2008). Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease. Nature 451, 720–724. 10.1038/nature06616 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Minten C., Alt C., Gentner M., Frei E., Deutsch U., Lyck R., et al. (2014). DARC shuttles inflammatory chemokines across the blood-brain barrier during autoimmune central nervous system inflammation. Brain 137, 1454–1469. 10.1093/brain/awu045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Monnier J., Lewén S., OéHara E., Huang K., Tu H., Butcher E. C., et al. (2012). Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells. J. Immunol. 189, 956–967. 10.4049/jimmunol.1102871 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Nakajima H., Fukuda K., Doi Y., Sugino M., Kimura F., Hanafusa T., et al. (2004). Expression of TH1/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. Eur. Neurol. 52, 162–168. 10.1159/000081856 [DOI] [PubMed] [Google Scholar]
  51. Nibbs R. J., Graham G. J. (2013). Immune regulation by atypical chemokine receptors. Nat Rev Immunol 13, 815–829. 10.1038/nri3544 [DOI] [PubMed] [Google Scholar]
  52. Nimmerjahn A., Kirchhoff F., Helmchen F. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314–1318. 10.1126/science.1110647 [DOI] [PubMed] [Google Scholar]
  53. Noh H., Jeon J., Seo H. (2014). Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain. Neurochem. Int. 69, 35–40. 10.1016/j.neuint.2014.02.008 [DOI] [PubMed] [Google Scholar]
  54. Novitzky-Basso I., Rot A. (2012). Duffy antigen receptor for chemokines and its involvement in patterning and control of inflammatory chemokines. Front. Immunol. 3:266. 10.3389/fimmu.2012.00266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Orihuela R., McPherson C. A., Harry G. J. (2016). Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 173, 649–665. 10.1111/bph.13139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Otero K., Vecchi A., Hirsch E., Kearley J., Vermi W., Del Prete A., et al. (2010). Nonredundant role of CCRL2 in lung dendritic cell trafficking. Blood 116, 2942–2949. 10.1182/blood-2009-12-259903 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Pabon M. M., Bachstetter A. D., Hudson C. E., Gemma C., Bickford P. C. (2011). CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease. J. Neuroinflammation 8:9. 10.1186/1742-2094-8-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Paolicelli R. C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., et al. (2011). Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456–1458. 10.1126/science.1202529 [DOI] [PubMed] [Google Scholar]
  59. Perry V. H., Teeling J. (2013). Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin. Immunopathol. 35, 601–612. 10.1007/s00281-013-0382-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Pruenster M., Mudde L., Bombosi P., Dimitrova S., Zsak M., Middleton J., et al. (2009). The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat. Immunol. 10, 101–108. 10.1038/ni.1675 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Przedborski S. (2010). Inflammation and Parkinson’s disease pathogenesis. Mov. Disord. 25, S55–S57. 10.1002/mds.22638 [DOI] [PubMed] [Google Scholar]
  62. Raes G., Noel W., Beschin A., Brys L., de Baetselier P., Hassanzadeh G. H. (2002). FIZZ1 and Ym as tools to discriminate between differentially activated macrophages. Dev. Immunol. 9, 151–159. 10.1080/1044667031000137629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Ransohoff R. M. (2016a). How neuroinflammation contributes to neurodegeneration. Science 353, 777–783. 10.1126/science.aag2590 [DOI] [PubMed] [Google Scholar]
  64. Ransohoff R. M. (2016b). A polarizing question: do M1 and M2 microglia exist? Nat. Neurosci. 19, 987–991. 10.1038/nn.4338 [DOI] [PubMed] [Google Scholar]
  65. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., et al. (2009). C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10, 514–523. 10.1038/ni.1716 [DOI] [PubMed] [Google Scholar]
  66. Rostène W., Dansereau M.-A., Godefroy D., Van Steenwinckel J., Reaux-Le Goazigo A., Mélik-Parsadaniantz S., et al. (2011). Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system. J. Neurochem. 118, 680–694. 10.1111/j.1471-4159.2011.07371.x [DOI] [PubMed] [Google Scholar]
  67. Rostène W., Kitabgi P., Parsadaniantz S. M. (2007). Chemokines: a new class of neuromodulator? Nat. Rev. Neurosci. 8, 895–903. 10.1038/nrn2255 [DOI] [PubMed] [Google Scholar]
  68. Sánchez-Alcañiz J. A., Haege S., Mueller W., Pla R., Mackay F., Schulz S., et al. (2011). Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron 69, 77–90. 10.1016/j.neuron.2010.12.006 [DOI] [PubMed] [Google Scholar]
  69. Schnabel R. B., Baumert J., Barbalic M., Dupuis J., Ellinor P. T., Durda P., et al. (2010). Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 115, 5289–5299. 10.1182/blood-2009-05-221382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Schwartz M., Kipnis J., Rivest S., Prat A. (2013). How do immune cells support and shape the brain in health, disease, and aging? J. Neurosci. 33, 17587–17596. 10.1523/JNEUROSCI.3241-13.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Shimoji M., Pagan F., Healton E. B., Mocchetti I. (2009). CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson’s disease. Neurotox. Res. 16, 318–328. 10.1007/s12640-009-9076-3 [DOI] [PubMed] [Google Scholar]
  72. Sierra A., Encinas J. M., Deudero J. J., Chancey J. H., Enikolopov G., Overstreet-Wadiche L. S., et al. (2010). Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell 7, 483–495. 10.1016/j.stem.2010.08.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Sofroniew M. V., Vinters H. V. (2010). Astrocytes: biology and pathology. Acta Neuropathol. 119, 7–35. 10.1007/s00401-009-0619-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Strobel S., Grunblatt E., Riederer P., Heinsen H., Arzberger T., Al-Sarraj S., et al. (2015). Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer’s disease progression: CX3CL1, TREM2, and PPARγ. J. Neural Transm. 122, 1069–1076. 10.1007/s00702-015-1369-5 [DOI] [PubMed] [Google Scholar]
  75. Sui Y., Stehno-Bittel L., Li S., Loganathan R., Dhillon N. K., Pinson D., et al. (2006). CXCL10-induced cell death in neurons: role of calcium dysregulation. Eur. J. Neurosci. 23, 957–964. 10.1111/j.1460-9568.2006.04631.x [DOI] [PubMed] [Google Scholar]
  76. Takeshita Y., Ransohoff R. M. (2012). Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol. Rev. 248, 228–239. 10.1111/j.1600-065x.2012.01127.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Tremblay M. È. (2011). The role of microglia at synapses in the healthy CNS: novel insights from recent imaging studies. Neuron Glia Biol. 7, 67–76. 10.1017/s1740925x12000038 [DOI] [PubMed] [Google Scholar]
  78. Ueno M., Fujita Y., Tanaka T., Nakamura Y., Kikuta J., Ishii M., et al. (2013). Layer V cortical neurons require microglial support for survival during postnatal development. Nat. Neurosci. 16, 543–551. 10.1038/nn.3358 [DOI] [PubMed] [Google Scholar]
  79. Uzawa A., Mori M., Hayakawa S., Masuda S., Nomura F., Kuwabara S. (2010). Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC Neurol. 10:113. 10.1186/1471-2377-10-113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Wolf S. A., Boddeke H. W., Kettenmann H. (2017). Microglia in physiology and disease. Annu. Rev. Physiol. 79, 619–643. 10.1146/annurev-physiol-022516-034406 [DOI] [PubMed] [Google Scholar]
  81. Xia M. Q., Bacskai B. J., Knowles R. B., Qin S. X., Hyman B. T. (2000). Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer’s disease. J. Neuroimmunol. 108, 227–235. 10.1016/s0165-5728(00)00285-x [DOI] [PubMed] [Google Scholar]
  82. Yang G., Meng Y., Li W., Yong Y., Fan Z., Ding H., et al. (2011). Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism. Brain Pathol. 21, 279–297. 10.1111/j.1750-3639.2010.00445.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Zabel B. A., Nakae S., Zuniga L., Kim J. Y., Ohyama T., Alt C., et al. (2008). Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J. Exp. Med. 205, 2207–2220. 10.1084/jem.20080300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Zlotnik A., Yoshie O. (2000). Chemokines: a new classification system and their role in immunity. Immunity 12, 121–127. 10.1016/S1074-7613(00)80165-X [DOI] [PubMed] [Google Scholar]
  85. Zuurman M. W., Heeroma J., Brouwer N., Boddeke H. W., Biber K. (2003). LPS-induced expression of a novel chemokine receptor (L-CCR) in mouse glial cells in vitro and in vivo. Glia 41, 327–336. 10.1002/glia.10156 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Aging Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES